ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 587
- Registration Number
- NCT03593213
- Locations
- 🇺🇸
Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸California Pharmaceutical Research Institute, Inc., Costa Mesa, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Torrance, California, United States
Expanded Access to Navitoclax
- Conditions
- MyelofibrosisAcute Lymphocytic Leukemia (ALL)Lymphoblastic Lymphoma
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03592576
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
- Conditions
- Bipolar I DisorderManiaDepression
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 901
- Registration Number
- NCT03573297
- Locations
- 🇺🇸
Synexus Clinical Research, Inc /ID# 232950, Atlanta, Georgia, United States
🇺🇸Atlanta Center for Medical Research /ID# 232832, Atlanta, Georgia, United States
🇺🇸NRC Research Institute /ID# 232741, Orange, California, United States
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 912
- Registration Number
- NCT03569293
- Locations
- 🇺🇸
Massachusetts General Hospital /ID# 200474, Boston, Massachusetts, United States
🇺🇸Dawes Fretzin, LLC /ID# 200366, Indianapolis, Indiana, United States
🇹🇷Erciyes University Medical Fac /ID# 204098, Melikgazi, Kayseri, Turkey
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1500
- Registration Number
- NCT03568318
- Locations
- 🇺🇸
University of Pittsburgh MC /ID# 206057, Pittsburgh, Pennsylvania, United States
🇨🇦Kirk Barber Research, CA /ID# 200329, Calgary, Alberta, Canada
🇧🇪IMTR - Grand Hopital de Charleroi /ID# 202029, Loverval, Belgium
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT03567616
- Locations
- 🇬🇧
Norfolk and Norwich Univ Hosp /ID# 202240, Norwich, Norfolk, United Kingdom
🇪🇸Hospital Universitario Vall d'Hebron /ID# 200967, Barcelona, Spain
🇺🇸Washington University-School of Medicine /ID# 201287, Saint Louis, Missouri, United States
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
- Conditions
- Hematologic Malignancies
- Interventions
- Drug: ethinyl estradiol/levonorgestrel
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT03557619
- Locations
- 🇺🇸
Duplicate_Henry Ford Health System /ID# 209090, Detroit, Michigan, United States
🇦🇺Peter MacCallum Cancer Centre-East Melbourne /ID# 225247, East Melbourne, Victoria, Australia
🇺🇸Gabrail Cancer Center Research /ID# 207039, Canton, Ohio, United States
A Long-Term Study of Rovalpituzumab Tesirine
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3
- Registration Number
- NCT03543358
- Locations
- 🇺🇸
Arizona Oncology Associates, PC-HOPE (Rudasill) /ID# 204818, Tucson, Arizona, United States
🇺🇸City of Hope National Medical Center /ID# 204885, Duarte, California, United States
🇺🇸Univ of Pittsburgh Med Ctr /ID# 204763, Pittsburgh, Pennsylvania, United States
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 270
- Registration Number
- NCT03539536
- Locations
- 🇺🇸
Veterans Healthcare System /ID# 215602, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital /ID# 203215, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center /ID# 208124, Boston, Massachusetts, United States
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 265
- Registration Number
- NCT03539744
- Locations
- 🇩🇰
Duplicate_Herlev Hospital /ID# 223221, Herlev, Hovedstaden, Denmark
🇺🇸Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407, Tucson, Arizona, United States
🇺🇸VA Central California Health Care System /ID# 200047, Fresno, California, United States